[Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
D000293:Adolescent; D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D011034:Podophyllotoxin; D011241:Prednisone
Association adriamycine, VM 26, cyclophosphamide et prédnisone dans le traitement des hématosarcomes.